HNN3.0
Register
Register
Register

BlooCell

Start-up

bloocell.com/Istanbul, Türkiye

About

Bloocell is a pioneering Turkish biotechnology company specializing in advanced 3D bioprinted tissue scaffolds for regenerative medicine. Founded in 2020, we have developed a proprietary 3D Bioprinting technology platform that creates biomimetic scaffolds with nano-to-micron scale precision, enabling true tissue regeneration across multiple clinical applications.

Core Technology & Expertise

Our manufacturing platform produces highly controlled fibrous architectures that replicate native tissue extracellular matrix (ECM) with unprecedented precision. Beyond structural mimicry, we integrate multi-functional surface modification strategies including:

  • Bioactive coatings for enhanced cell adhesion, proliferation, and differentiation

  • Controlled drug delivery systems for localized therapeutic release (antibiotics, growth factors, anti-inflammatory agents)

  • Anti-fouling and antimicrobial functionalization for infection prevention

  • Patient-specific customization through computational design and additive manufacturing

Clinical & Commercial Validation

Bloocell holds Turkey's first and only clinical approval for 3D bioprinted tissue scaffolds. Our bone and dental regeneration products (BCRM) are currently in active clinical use, demonstrating 2-3x faster healing compared to conventional treatments with over 4000+ patients. This clinical track record positions us uniquely among domestic medical device companies in the regenerative medicine sector.

Representatives

Research and Development Scientist

BlooCell

Marketplace (1)

  • Project cooperation

    3D-Bioprinted Scaffolds for Drug Delivery & Tissue Regeneration Partnership

    To develop drug-eluting 3D printed scaffolds for tissue regeneration. Clinically approved platform ready for functionalization.

    • Consortium/Coordinator seeks Partners
    • Partner seeks Consortium/Coordinator
    • DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-15: Scaling up innovation in cardiovascular health
    • DESTINATION 6: HORIZON-HLTH-2026-01-IND-03: Regulatory science to support translational development of patient-centred health technologies
    • DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-03: Integrating New Approach Methodologies (NAMs) to advance biomedical research and regulatory testing
    • DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-05: Pilot actions for follow-on funding: Leveraging EU-funded collaborative research in regenerative medicine
    • DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-07: Establishing a European network of Centres of Excellence (CoEs) for Advanced Therapies Medicinal Products (ATMPs)
    • DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-06: Support to European Research Area (ERA) action on accelerating New Approach Methodologies (NAMs) to advance biomedical research and testing of medicinal products and medical devices
    Author

    Research and Development Scientist at BlooCell

    Istanbul, Türkiye